Moderna Advances Coronavirus Vaccine to the Next Phase
Clinical-stage biotech Moderna (NASDAQ: MRNA) announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to move its COVID-19 vaccine to phase 2 and late-stage studies if supported by safety data from a phase 1 trial underway now.
Moderna has received feedback from the FDA on the design of the study and expects to begin the phase 2 trial of its vaccine candidate mRNA-1273 in the next two months. The trial will enroll 600 participants, who will be randomly assigned to groups receiving a placebo or one of two dose levels of the vaccine, given as two different vaccinations 28 days apart. Half of the participants will be between the ages of 18 and 55 and the other half 55 or older. Participants will be followed for a year after the last vaccinations.
Image source: Getty Images.
Source Fool.com
